Thomas B Graham

US Patent:

20220402916, Dec 22, 2022

Filed:

Sep 18, 2020

Appl. No.:

17/761433

Inventors:

- Rahway NJ, US
Thomas H. Graham - Somerville MA, US
Xiaoshen Ma - Boston MA, US
Zahid Hussain - Dayton NJ, US
Mihir Mandal - Westfield NJ, US
Symon Gathiaka - Waltham MA, US
Yongxin Han - Needham MA, US
David L. Sloman - Newton MA, US

International Classification:

C07D 471/04
A61P 35/00

Abstract:

Provided are compounds of Formula (I)or a pharmaceutically acceptable salt thereof, wherein Y, CY, R, R, R, R, R, R, R, R, R, and the subscripts m, n, and q are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treatment of cancer. Also provided are pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. Also provided are methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

US Patent:

20230114847, Apr 13, 2023

Filed:

Nov 29, 2022

Appl. No.:

18/070889

Inventors:

- Boston MA, US
Carl Ramey - Westborough MA, US
Michael Gould - Woburn MA, US
Thomas Graham - Cambridge MA, US
Darius Bunandar - Boston MA, US
Ryan Braid - Cambridge MA, US
Mykhailo Tymchenko - Malden MA, US

Assignee:

Lightmatter, Inc. - Boston MA

International Classification:

G02B 6/122
G02B 6/12
H01L 21/027
G02B 6/13
G02B 6/136

Abstract:

Described herein are photonic communication platforms that can overcome the memory bottleneck problem, thereby enabling scaling of memory capacity and bandwidth well beyond what is possible with conventional computing systems. Some embodiments provide photonic communication platforms that involve use of photonic modules. Each photonic module includes programmable photonic circuits for placing the module in optical communication with other modules based on the needs of a particular application. The architecture developed by the inventors relies on the use of common photomask sets (or at least one common photomask) to fabricate multiple photonic modules in a single wafer. Photonic modules in multiple wafers can be linked together into a communication platform using optical or electronic means.

US Patent:

20230054411, Feb 23, 2023

Filed:

Nov 26, 2019

Appl. No.:

17/294836

Inventors:

Yonglian ZHANG - Kenilworth NJ, US
Amjad ALI - Kenilworth NJ, US
Jared CUMMING - Winchester MA, US
Duane DEMONG - Boston MA, US
Qiaolin DENG - Kenilworth NJ, US
Thomas H. GRAHAM - Boston MA, US
Elisabeth HENNESSY - Boston MA, US
Matthew A. LARSEN - Boston MA, US
Kun LIU - Boston MA, US
Ping LIU - Boston MA, US
Umar Faruk MANSOOR - Boston MA, US
Jianping PAN - Kenilworth NJ, US
Christopher W. PLUMMER - Kenilworth NJ, US
Aaron SATHER - Boston MA, US
Uma SWAMINATHAN - Boston MA, US
Huijun WANG - Westfield NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/519
A61K 39/395
C07D 471/04
C07D 519/00
A61K 31/55

Abstract:

In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2and/or A2receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2receptor and/or the adenosine A2receptor.

US Patent:

20210395255, Dec 23, 2021

Filed:

Nov 15, 2019

Appl. No.:

17/292511

Inventors:

Zachary G. BRILL - Boston MA, US
Amjad ALI - Kenilworth NJ, US
Jared CUMMING - Winchester MA, US
Duane DEMONG - Boston MA, US
Qiaolin DENG - Kenilworth NJ, US
Thomas H. GRAHAM - Boston MA, US
Rongze KUANG - Kenilworth NJ, US
Yeon-Hee LIM - South San Francisco CA, US
Christopher W. PLUMMER - Kenilworth NJ, US
Jenny Lorena RICO DUQUE - Boston MA, US
Huijun WANG - Kenilworth NJ, US
Yonglian ZHANG - Kenilworth NJ, US
Kake ZHAO - Kenilworth NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04
C07K 16/28

Abstract:

In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): or and pharmaceutically acceptable salts thereof, wherein, R, R, and Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

US Patent:

20210278590, Sep 9, 2021

Filed:

May 6, 2021

Appl. No.:

17/313415

Inventors:

- Boston MA, US
Carl Ramey - Westborough MA, US
Michael Gould - Boston MA, US
Thomas Graham - Cambridge MA, US
Darius Bunandar - Boston MA, US
Ryan Braid - Cambridge MA, US
Mykhailo Tymchenko - Malden MA, US

Assignee:

Lightmatter, Inc. - Boston MA

International Classification:

G02B 6/122
G02B 6/12
H01L 21/027
G02B 6/13
G02B 6/136

Abstract:

Described herein are photonic communication platforms that can overcome the memory bottleneck problem, thereby enabling scaling of memory capacity and bandwidth well beyond what is possible with conventional computing systems. Some embodiments provide photonic communication platforms that involve use of photonic modules. Each photonic module includes programmable photonic circuits for placing the module in optical communication with other modules based on the needs of a particular application. The architecture developed by the inventors relies on the use of common photomask sets (or at least one common photomask) to fabricate multiple photonic modules in a single wafer. Photonic modules in multiple wafers can be linked together into a communication platform using optical or electronic means.

US Patent:

20210122764, Apr 29, 2021

Filed:

Oct 27, 2020

Appl. No.:

17/081477

Inventors:

- Rahway NJ, US
Symon Gathiaka - Waltham MA, US
Yongxin Han - Needham MA, US
Xiaoshen Ma - Boston MA, US
Ryan D. Otte - Natick MA, US
David L. Sloman - Newton MA, US
Thomas H. Graham - Somerville MA, US
Timothy Henderson - Natick MA, US
Elizabeth Hennessy - Weston MA, US
Anandan Palani - Needham MA, US

International Classification:

C07D 498/22
A61P 35/00
A61K 31/519
C07D 471/22
C07D 519/00

Abstract:

The disclosure provides compounds of Formula (I)or a pharmaceutically acceptable salt thereof, wherein W, W, Y, Z, M, L, C, C, R, R, R, R, R, R, Rand the subscripts m, n, q, and r are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12C mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

US Patent:

20200284981, Sep 10, 2020

Filed:

Mar 5, 2020

Appl. No.:

16/810573

Inventors:

- Boston MA, US
Carl Ramey - Westborough MA, US
Michael Gould - Boston MA, US
Thomas Graham - Cambridge MA, US
Darius Bunandar - Boston MA, US
Ryan Braid - Cambridge MA, US
Mykhailo Tymchenko - Malden MA, US

Assignee:

Lightmatter, Inc. - Boston MA

International Classification:

G02B 6/122
G02B 6/12
H01L 21/027
G02B 6/13

Abstract:

Described herein are photonic communication platforms that can overcome the memory bottleneck problem, thereby enabling scaling of memory capacity and bandwidth well beyond what is possible with conventional computing systems. Some embodiments provide photonic communication platforms that involve use of photonic modules. Each photonic module includes programmable photonic circuits for placing the module in optical communication with other modules based on the needs of a particular application. The architecture developed by the inventors relies on the use of common photomask sets (or at least one common photomask) to fabricate multiple photonic modules in a single wafer. Photonic modules in multiple wafers can be linked together into a communication platform using optical or electronic means.

US Patent:

20190330239, Oct 31, 2019

Filed:

Nov 13, 2017

Appl. No.:

16/461902

Inventors:

Thomas H. Graham - Boston MA, US
Wensheng LIU - Edison NJ, US
Clare TUDGE - Chatham NJ, US
Andreas VERRAS - New York NY, US
Jinlong JIANG - Kenilworth NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 515/08
C07D 409/12
C07D 401/12
C07D 403/12
C07D 231/56
C07D 405/12
C07D 487/04
C07D 417/12
C07D 413/12
C07D 409/14

Abstract:

The present invention relates to a compound represented by formula I′: and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 (“DGAT2”) and may be useful in the treatment, prevention and suppression of diseases mediated by DGAT2. The compounds of the present invention may be useful in the treatment of hepatic steatosis, diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions.

Address:

16 Knowlton St, Boston, MA 02127

VIN:

1GKFK63877J216221

Make:

GMC

Model:

YUKON

Year:

2007